Menu
Back to Journals » Vascular Health and Risk Management » Volume 13
Original Research
Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 7,820 | Dovepress* | 6,741+ | 1,625 | 8,366 | |
| PubMed Central* | 1,079 | 305 | 1,384 | ||
| Totals | 7,820 | 1,930 | 9,750 | ||
| *Since 6 July 2017 | |||||
View citations on PubMed Central and Google Scholar